Claims for Patent: 8,287,851

Summary for Patent: 8,287,851

Title:	Use of interleukin 17E for the treatment of cancer
Abstract:	The use of interleukin 17E to inhibit tumor growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumor growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.
Inventor(s):	Wright; Jim A. (Oakville, CA), Young; Aiping H. (North York, CA), Lee; Yoon (Mississauga, CA), Cao; Ming Yu (Mississauga, CA)
Assignee:	Lorus Therapeutics Inc. (Toronto, CA)
Application Number:	11/817,914
Patent Claims:	1. A method of treating a tumour in a subject in need thereof comprising administering an effective amount of an interleukin 17E (IL-17E) polypeptide to said subject. 2. The method according to claim 1, wherein said tumour is a tumour associated with a mucosal tissue. 3. The method according to claim 1, wherein said tumour is a colon tumour, breast tumour, ovarian tumour, cervical tumour, endometrial tumour, lung tumour, gastric tumour, oral tumour, oesophageal tumour, or prostate tumour. 4. The method according to claim 1, wherein said tumour is a solid tumour. 5. The method according to claim 4, wherein said tumour is a melanoma, a pancreatic tumour, an ovarian tumour, a lung tumour, a breast tumour or a colon tumour. 6. The method according to claim 4, wherein said tumour is a pancreatic tumour. 7. The method according to claim 1, wherein said IL-17E polypeptide has the amino acid sequence of the mature polypeptide as set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3. 8. The method according to claim 1, wherein said IL-17E polypeptide has an amino acid sequence as set forth in SEQ ID NO:1, from amino acid 33 to 177. 9. The method according to claim 1, wherein said IL-17E polypeptide is the mature form of human IL-17E. 10. A method of treating a tumour in a subject in need thereof comprising administering an effective amount of an interleukin 17E (IL-17E) polypeptide in combination with an effective amount of one or more anti-cancer therapeutics to said subject. 11. The method according to claim 10, wherein said tumour is a tumour associated with a mucosal tissue. 12. The method according to claim 10, wherein said tumour is a colon tumour, breast tumour, ovarian tumour, cervical tumour, endometrial tumour, lung tumour, gastric tumour, oral tumour, oesophageal tumour, or prostate tumour. 13. The method according to claim 10, wherein said tumour is a solid tumour. 14. The method according to claim 13, wherein said tumour is a melanoma, a pancreatic tumour, an ovarian tumour, a lung tumour, a breast tumour or a colon tumour. 15. The method according to claim 13, wherein said tumour is a pancreatic tumour. 16. The method according to claim 10, wherein said IL-17E polypeptide has the amino acid sequence of the mature polypeptide as set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3. 17. The method according to claim 10, wherein said IL-17E polypeptide has an amino acid sequence as set forth in SEQ ID NO:1, from amino acid 33 to 177. 18. The method according to claim 10, wherein said IL-17E polypeptide is the mature form of human IL-17E. 19. The method according to claim 10, wherein said one or more anticancer therapeutics is one or more chemotherapeutic drugs, one or more immunotherapeutics, or a combination thereof. 20. The method according to claim 10, wherein at least one of said anticancer therapeutics is a chemotherapeutic. 21. The method according to claim 20, wherein said chemotherapeutic is a broad spectrum chemotherapeutic. 22. The method according to claim 10, wherein at least one of said anticancer therapeutics is an immunotherapeutic. 23. The method according to claim 22, wherein said immunotherapeutic is a monoclonal antibody. 24. The method according to claim 10, wherein at least one of said anticancer therapeutics is dacarbazine, cisplatin, docetaxel, erlotinib, paclitaxel, gemcitabine, CPT-11 or bevacizumab. 25. The method according to claim 10, wherein said one or more anticancer therapeutics is gemcitabine. 26. The method according to claim 10, wherein said tumour is a melanoma, and said one or more anticancer therapeutics is dacarbazine. 27. The method according to claim 10, wherein said tumour is a pancreatic tumour, and said one or more anticancer therapeutics is gemcitabine. 28. The method according to claim 10, wherein said tumour is an ovarian tumour, and said one or more anticancer therapeutics is cisplatin. 29. The method according to claim 10, wherein said tumour is a lung tumour, and said one or more anticancer therapeutics is docetaxel or erlotinib. 30. The method according to claim 10, wherein said tumour is a breast tumour, and said one or more anticancer therapeutics is cisplatin or paclitaxel. 31. The method according to claim 10, wherein said tumour is a colon tumour, and said one or more anticancer therapeutics is CPT-11 or bevacizumab.

Details for Patent 8,287,851

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2025-03-08